ABSTRACT
BACKGROUND AND AIMS: In Peru, the estimated prevalence of human immunodeficiency virus (HIV) and human T-lymphotropic virus-1 (HTLV-1) co-infection has been reported to be as high as 18%. Despite the endemicity of HTLV-1 in Peru, few studies have assessed the impact of HIV/HTLV-1 co-infection. Our study compared socio-demographic and clinical characteristics, and mortality rates between HIV-infected and HIV/HTLV-1 co-infected patients. METHODS: We reviewed the medical records of patients aged 18 years and older belonging to the HIV and HTLV-1 cohorts in Lima during a 30-year period: 1989-2019. Each HIV/HTLV-1 co-infected patient was randomly matched with two HIV-infected patients with similar characteristics (same sex, age ± 5 years, and same year of HIV diagnosis). Allegedly co-infected patients without a confirmatory diagnosis of HIV and HTLV-1 were excluded. Most of the patients in the HIV-infected group did not have a negative test result for HTLV-1 infection, so we used two probabilistic sensitivity analysis models to correct for potential HTLV-1 exposure misclassification bias in the group of HIV-infected patients. RESULTS: Of 162 patients enrolled, 54 were HIV/HTLV-1 co-infected and 108 were HIV-infected. The median age was 42 years (IQR = 34-51 years) and the majority were male (61.1%), single (44.4%), heterosexual (71%), born in Lima (58%), educated at the secondary school level (55.6%), and receiving antiretroviral treatment (91.4%). HIV/HTLV-1 co-infection was associated with an increased risk of death (HR: 11.8; 95% CI: 1.55-89.00; p = 0.017) while antiretroviral treatment was associated with a decreased risk of death (HR: 0.03; 95% CI: 0.003-0.25; p = 0.001). The overall mortality rate was 13.6 per 100 persons and the survival time for co-infected patients (median = 14.19 years) was significantly shorter than that of HIV-infected patients (median = 23.83 years) (p < 0.001). CONCLUSIONS: HIV/HTLV-1 co-infected patients had a significantly shorter survival time compared to HIV-infected patients, suggesting that the immune alterations caused by HTLV-1 in CD4 cell count may have contributed to late initiation of antiretroviral treatment and prophylaxis against opportunistic infections over the decades, and thus reducing their benefits in these patients.
ABSTRACT
Kaposi's sarcoma (KS) is the most frequent cancer in people living with HIV. Research on this condition is scarce in the region, therefore, this article aimed to describe the demographic, clinical and therapeutic characteristics of patients with HIV who developed KS at the Cayetano Heredia Hospital between 2000 and 2018. A total of 129 KS cases were identified, with a median age of 33 years, predominantly males with 92% (119/129), and mostly men who have sex with men (MSM). The median time from HIV diagnosis to KS diagnosis was five months, associated with a CD4 lymphocyte count of 64 cells/µL (IQR: 33-185) at KS diagnosis. Cutaneous involvement was the most common presentation; however, at least half also had the visceral form.
El sarcoma de Kaposi (SK) es el cáncer más frecuente en las personas que viven con VIH. Las investigaciones sobre esta condición son escasas en la región, por lo que, el objetivo de este artículo fue describir las características demográficas, clínicas y terapéuticas de los pacientes con VIH que desarrollaron SK en el Hospital Cayetano Heredia entre el 2000 y 2018. Se identificaron 129 casos de SK, con una mediana de edad de 33 años, con predominio en varones con el 92% (119/129), y en su mayoría hombres que tienen sexo con hombres (HSH). La mediana de tiempo desde el diagnóstico de VIH hasta el del SK fue de cinco meses, asociado con un recuento de linfocitos CD4 de 64 células/µL (RIC: 33-185) al momento del diagnóstico de SK. El compromiso cutáneo fue el más común; sin embargo, al menos la mitad de ellos también tuvo la forma visceral.
Subject(s)
HIV Infections , Sarcoma, Kaposi , Sexual and Gender Minorities , Humans , Male , Adult , Female , Sarcoma, Kaposi/diagnosis , Sarcoma, Kaposi/epidemiology , Homosexuality, Male , Hospitals , HIV Infections/complications , HIV Infections/epidemiologyABSTRACT
RESUMEN El sarcoma de Kaposi (SK) es el cáncer más frecuente en las personas que viven con VIH. Las investigaciones sobre esta condición son escasas en la región, por lo que, el objetivo de este artículo fue describir las características demográficas, clínicas y terapéuticas de los pacientes con VIH que desarrollaron SK en el Hospital Cayetano Heredia entre el 2000 y 2018. Se identificaron 129 casos de SK, con una mediana de edad de 33 años, con predominio en varones con el 92% (119/129), y en su mayoría hombres que tienen sexo con hombres (HSH). La mediana de tiempo desde el diagnóstico de VIH hasta el del SK fue de cinco meses, asociado con un recuento de linfocitos CD4 de 64 células/µL (RIC: 33-185) al momento del diagnóstico de SK. El compromiso cutáneo fue el más común; sin embargo, al menos la mitad de ellos también tuvo la forma visceral.
ABSTRACT Kaposi's sarcoma (KS) is the most frequent cancer in people living with HIV. Research on this condition is scarce in the region, therefore, this article aimed to describe the demographic, clinical and therapeutic characteristics of patients with HIV who developed KS at the Cayetano Heredia Hospital between 2000 and 2018. A total of 129 KS cases were identified, with a median age of 33 years, predominantly males with 92% (119/129), and mostly men who have sex with men (MSM). The median time from HIV diagnosis to KS diagnosis was five months, associated with a CD4 lymphocyte count of 64 cells/μL (IQR: 33-185) at KS diagnosis. Cutaneous involvement was the most common presentation; however, at least half also had the visceral form.
Subject(s)
Humans , Male , Female , Adult , Sarcoma, Kaposi/epidemiology , AIDS-Related Opportunistic Infections/epidemiology , Peru/epidemiology , Sarcoma, Kaposi/virology , Cohort Studies , AIDS-Related Opportunistic Infections/virology , CD4 Lymphocyte Count , Viral Load , Age and Sex DistributionABSTRACT
This study was carried out to describe and compare the demographic, clinical, and therapeutic characteristics of HIV patients who developed some cancer. We identified 276 cancer cases diagnosed at Hospital Cayetano Heredia between 2000 and 2018. 80,8% (223/276) had AIDS-defining-cancers (ADCs), being Kaposi's Sarcoma the most frequent type; meanwhile, among non-AIDS-defining-cancers (NADCs), the most frequent was Hodgkin lymphoma. The median age was 36,5 years, being highest among the cases diagnosed with NADCs. Concerning CD4 lymphocyte counts, the median among ADCs was much lower than NADCs, 87,5 cells/µl and 216 cells/µl, respectively. Therefore, NADCs cases have a longer history of HIV infection, and an older age at cancer diagnosis, as well as higher CD4 cells counts.
El objetivo del estudio fue describir las características demográficas, clínicas y terapéuticas de pacientes con VIH-SIDA que desarrollaron algún tipo de cáncer. Se identificaron 276 casos de cáncer diagnosticados en el Hospital Nacional Cayetano Heredia entre el 2000 y 2018. El 80,8% (223/276) correspondieron a neoplasias definitorias de sida (NDS), siendo el más frecuente el sarcoma de Kaposi; mientras que, entre las neoplasias no definitorias de sida (NNDS), el más frecuente fue el linfoma de Hodgkin. La mediana de edad fue 36,5 años, siendo más alta entre los casos diagnosticados de NNDS. Con respecto al nivel de linfocitos CD4 al diagnóstico de cáncer, la mediana entre las NDS fue mucho menor que las NNDS, 87,5 células/µL y 216 células/µL, respectivamente. Por tanto, las NNDS tuvieron una historia más larga de infección por VIH, y una edad más avanzada al diagnóstico de cáncer, así como niveles de células CD4 más altos.
Subject(s)
Acquired Immunodeficiency Syndrome , HIV Infections , Neoplasms , Sarcoma, Kaposi , Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/epidemiology , Adult , Aged , HIV Infections/complications , HIV Infections/epidemiology , Hospitals , Humans , Peru/epidemiology , Referral and Consultation , Risk Factors , Sarcoma, Kaposi/diagnosis , Sarcoma, Kaposi/epidemiologyABSTRACT
This study aims to describe knowledge on HIV and antiretroviral (ARV) treatment and psychosocial factors among people living with HIV (PLWH) in Lima, Perú, to explore characteristics associated to this knowledge, and determine its impact on sustained viral suppression. A cross-sectional survey was conducted among 171 PLWH at the largest referral health care center in Lima. The psychosocial factors measured were depression, risk of alcoholism, use of illegal drugs and disclosure. A participant had "poor knowledge" when less than 80% of replies were correct. Sustained viral suppression was defined as two consecutive viral loads under 50 copies/mL. A total of 49% and 43% had poor HIV and ARV knowledge respectively; 48% of the study population screened positive for depression and 27% reported feeling unsupported by the person they disclosed to. The largest gaps in HIV and ARV knowledge were among 98 (57%) that did not recognize that HIV increased the risk of cancer and among 57 (33%) participants that did not disagree with the statement that taking a double dose of ARV if they missed one. Moderate depression was significantly associated to poor HIV and ARV knowledge. Non-disclosure and being on ARVs for less than 6 months were associated with not achieving sustained viral suppression. Our findings highlight important HIV and ARV knowledge gaps of PLWH and a high burden of psychosocial problems, especially of depression, among PLWH in Lima, Peru. Increasing knowledge and addressing depression and disclosure could improve care of PLWH.
Subject(s)
Depression/epidemiology , HIV Infections/epidemiology , Viral Load , Adolescent , Adult , Anti-Retroviral Agents/therapeutic use , Depression/drug therapy , Depression/etiology , Depression/psychology , Disclosure , Female , HIV Infections/complications , HIV Infections/drug therapy , HIV Infections/psychology , Humans , Male , Middle Aged , Peru/epidemiology , Young AdultABSTRACT
Due to a huge crisis extensive to health services many Venezuelan people living with HIV (PLWH) had migrated abroad, including Peru where favorable laws were in place until June 2019. We describe the health status and epidemiological trends of PLWH from Venezuela at an HIV program in Lima. We analyzed baseline and follow-up data of all Venezuelan PLWH enrolled in our HIV program from January 2017 to December 2019. A cross-sectional study in a subsample served to describe ARV adherence and context of migration. Between 2017-2019 our HIV Program registered 398 Venezuelan PLWH, representing 20% of the 2018 annual enrollments; numbers decreased since mid-2019. The median age was 30 years (IQR 26;37) and 90.5% were men. Between 2017 and 2019, the proportion with diagnosis in Peru increased from 14.3% to 60.9%; of AIDS stage at entry, from 8.8% to 27.2%. By December 2019, 182/250 (72.8%) were still in care, and 43 (10.8%) had not started ART. Viral suppression evaluated in 195, was achieved in 71.8%. From 2017 to 2019, migrant PLWH arrived in worsened clinical conditions, with increasing diagnosis in Peru; the flow of migrant PLWH entering care diminished with less favorable laws. Viral suppression rates were suboptimal.
Subject(s)
HIV Infections , Transients and Migrants , Adult , Cross-Sectional Studies , HIV Infections/drug therapy , HIV Infections/epidemiology , Hospitals , Humans , Male , Peru/epidemiologyABSTRACT
El objetivo del estudio fue describir las características demográficas, clínicas y terapéuticas de pacientes con VIH-SIDA que desarrollaron algún tipo de cáncer. Se identificaron 276 casos de cáncer diagnosticados en el Hospital Nacional Cayetano Heredia entre el 2000 y 2018. El 80,8% (223/276) correspondieron a neoplasias definitorias de sida (NDS), siendo el más frecuente el sarcoma de Kaposi; mientras que, entre las neoplasias no definitorias de sida (NNDS), el más frecuente fue el linfoma de Hodgkin. La mediana de edad fue 36,5 años, siendo más alta entre los casos diagnosticados de NNDS. Con respecto al nivel de linfocitos CD4 al diagnóstico de cáncer, la mediana entre las NDS fue mucho menor que las NNDS, 87,5 células/µL y 216 células/µL, respectivamente. Por tanto, las NNDS tuvieron una historia más larga de infección por VIH, y una edad más avanzada al diagnóstico de cáncer, así como niveles de células CD4 más altos.
This study was carried out to describe and compare the demographic, clinical, and therapeutic characteristics of HIV patients who developed some cancer. We identified 276 cancer cases diagnosed at Hospital Cayetano Heredia between 2000 and 2018. 80,8% (223/276) had AIDS-defining-cancers (ADCs), being Kaposi's Sarcoma the most frequent type; meanwhile, among non-AIDS-defining-cancers (NADCs), the most frequent was Hodgkin lymphoma. The median age was 36,5 years, being highest among the cases diagnosed with NADCs. Concerning CD4 lymphocyte counts, the median among ADCs was much lower than NADCs, 87,5 cells/µl and 216 cells/µl, respectively. Therefore, NADCs cases have a longer history of HIV infection, and an older age at cancer diagnosis, as well as higher CD4 cells counts.
ABSTRACT
INTRODUCTION: In patients with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) gait disturbance is a predominant feature that leads to falls and fractures, which can further aggravate disability. We sought to evaluate the impact of fractures and orthopedic surgeries in patients with HAM/TSP. METHODS: We retrieved the medical records of HAM/TSP patients enrolled in our study center's HTLV-1 clinical cohort between 1989-2018. The selection criteria included: (1) diagnosis of HTLV-1 infection using two enzyme-linked immunosorbent assays and/or a confirmatory test, (2) clinical diagnosis of HAM/TSP by neurological assessment, and (3) fractures associated with HAM/TSP. RESULTS: We identified 24 cases of fractures, 70% of which were females. The median age at the time of fracture was 60 years (IQR=24). Six cases reported fractures in patients under 45 years old. Ten patients (42%) had hip/coccyx fractures, seven (29%) were in the lower extremities, and four (17%) in the upper extremities. Half of these patients reported the use of wheelchairs. Five patients who had previously used canes required the use of wheelchairs after the reported fracture. Eight patients underwent corrective orthopedic surgery as a result of the fracture. CONCLUSIONS: For HAM/TSP patients, fractures are a complication that can exacerbate their severe impairment.
Subject(s)
HTLV-I Infections , Human T-lymphotropic virus 1 , Orthopedic Procedures , Paraparesis, Tropical Spastic , Cohort Studies , Female , Humans , Male , Middle AgedABSTRACT
BACKGROUND: Vertical transmission of HTLV-1 could lead to the early development of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). This significantly affects quality of life and increases morbimortality. OBJECTIVE: To describe the epidemiological and clinical characteristics of patients with early-onset HAM/TSP, defined as disease onset before 20 years of age. METHODS: This is a retrospective study from an HTLV-1 clinical cohort between 1989 and 2019. We searched for medical records of patients with (1) diagnosis of HTLV-1 infection using two ELISA and/or one Western blot, (2) clinical diagnosis of HAM/TSP by neurological assessment, and (3) HAM/TSP symptom-onset before 20 years of age. RESULTS: A total of 38 cases were identified in the cohort; 25 were female (66%). The median age of onset was 14 years old. 31 (82%) cases had HTLV-1 testing done among family members; 22 out of 25 tested mothers (88%) were HTLV-1 positive. Most patients (27/34) were breastfed for more than one year. Disease progression measured through EDSS and IPEC-1 showed an upward trend towards worsening spasticity with 18 patients (47%) eventually requiring mobility aids. CONCLUSIONS: Cases of early-onset HAM/TSP are not of rare occurrence, which translates into many more years of dependency, the use of mobility aids, and increased overall morbidity.
ABSTRACT
Abstract INTRODUCTION In patients with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) gait disturbance is a predominant feature that leads to falls and fractures, which can further aggravate disability. We sought to evaluate the impact of fractures and orthopedic surgeries in patients with HAM/TSP. METHODS: We retrieved the medical records of HAM/TSP patients enrolled in our study center's HTLV-1 clinical cohort between 1989-2018. The selection criteria included: (1) diagnosis of HTLV-1 infection using two enzyme-linked immunosorbent assays and/or a confirmatory test, (2) clinical diagnosis of HAM/TSP by neurological assessment, and (3) fractures associated with HAM/TSP. RESULTS: We identified 24 cases of fractures, 70% of which were females. The median age at the time of fracture was 60 years (IQR=24). Six cases reported fractures in patients under 45 years old. Ten patients (42%) had hip/coccyx fractures, seven (29%) were in the lower extremities, and four (17%) in the upper extremities. Half of these patients reported the use of wheelchairs. Five patients who had previously used canes required the use of wheelchairs after the reported fracture. Eight patients underwent corrective orthopedic surgery as a result of the fracture. CONCLUSIONS: For HAM/TSP patients, fractures are a complication that can exacerbate their severe impairment.
Subject(s)
Humans , Male , Female , Human T-lymphotropic virus 1 , HTLV-I Infections , Paraparesis, Tropical Spastic , Orthopedic Procedures , Cohort Studies , Middle AgedABSTRACT
Patient-nominated supporters can potentially improve the continuum of HIV care. We retrospectively determined factors associated with having a patient-nominated supporter among people living with HIV (PLWH), and its association with retention in care and viral suppression. We analysed registries of adults evaluated by social workers (n = 1345) at a referral hospital in Peru between 2011-2014. Nondisclosure of HIV status was associated with lacking supporters (aPR: 5.41, 95% CI: 3.83-7.64). Retention in care was 76.4% and 34.2% after one and two years of enrolment, respectively. PLWH with supporters were more likely to be retained in care after two years (aRR = 1.36, 95% CI: 1.02-1.81), but not after one year (aRR = 1.10, 95% CI: 0.98-1.23) compared to PLWH without supporters. Having supporters who were parents or friends was associated with an increased probability of being retained in care after one and two years of enrolment. Viral suppression after one year of enrolment was 58.7%. Having a supporter was not associated with viral suppression (aRR = 1.18, 95% CI: 0.99-1.41), but PLWH with supporters were more likely to have viral load measurements (p = 0.005). Patient-nominated supporters appear beneficial for engagement in HIV care; these benefits may be related to the nature of their relationship with PLWH.
Subject(s)
HIV Infections/therapy , Patient Participation/methods , Social Support , Adolescent , Adult , Family , Female , Follow-Up Studies , Friends , HIV Infections/psychology , HIV Infections/virology , Humans , Male , Patient Compliance/psychology , Peru , Registries , Retrospective Studies , Social Workers , Tertiary Care Centers , Viral Load , Young AdultABSTRACT
INTRODUCTION: Based on the hypothesis that HIV programs struggle to deliver health services that harmonize necessities of treatment and prevention, we described the outcomes of routinely provided HIV testing to partners of people living with HIV (PLWH) through a secondary analysis of routine data collected at a public hospital in Lima, Peru. METHODS: Among PLWH enrolled in the study center's HIV program between 2005 and 2014, we identified index cases (IC): PLWH who reported a unique partner not previously enrolled. We grouped partners according to their HIV status as reported by IC and collected data on HIV testing, clinical characteristics and admissions. The main outcome was the frequency of HIV testing among partners with reported unknown/seronegative HIV status. RESULTS: Out of 1586 PLWH who reported a unique partner at enrollment, 171 had a previously enrolled partner, leaving 1415 (89%) IC. HIV status of the partner was reported as unknown in 571 (40%), seronegative in 325 (23%) and seropositive in 519 (37%). Out of 896 partners in the unknown/seronegative group, 72 (8%) had HIV testing, 42/72 (58%) tested within three months of IC enrollment. Among the 49/72 (68%) who tested positive for HIV, 33 (67%) were enrolled in the HIV program. The proportion in WHO clinical stage IV was lower in enrolled partners compared to IC (37% vs 9%, p = 0.04). Non-tested partners (824) were likely reachable by the hospital, as 297/824 (36%) of their IC were admitted in the study center at least once, 51/243 (21%) female IC had received pregnancy care at the study center, and 401/692 (64%) of IC on antiretroviral therapy had achieved viral suppression, implying frequent visits to the hospital for pill pick-up. CONCLUSION: In this setting, HIV testing of partners of PLWH was suboptimal, illustrating missed opportunities for HIV control. Integration of HIV strategies in primarily clinical-oriented services is a challenging need.
Subject(s)
HIV Infections/diagnosis , HIV Infections/prevention & control , Mass Screening , Sexual Partners , Adult , Female , HIV Seronegativity , Humans , Male , PeruABSTRACT
INTRODUCTION: The first-line combination therapy for HIV-associated cryptococcal meningitis (CM), a condition of high mortality particularly in the first two weeks of treatment, consists of amphotericin B plus flucytosine (5-FC). Given that 5-FC remains unavailable in many countries, the knowledge of factors influencing mycological clearance in patients treated with second-line therapy could contribute to effective management. OBJECTIVES: To determine the factors associated with the clearance of Cryptococcus sp. from the cerebrospinal fluid by the second week of effective antifungal therapy (early mycological clearance) in HIV-associated CM. METHODS: Retrospective cohort study based on secondary data corresponding to HIV-associated CM cases hospitalized at a tertiary health care center in Lima, Peru where 5-FC remains unavailable. Risk factors associated with early mycological clearance were analyzed by generalized linear regression models. RESULTS: From January 2000 to December 2013, 234 individuals were discharged with a diagnosis of HIV-associated CM; in 215 we retrieved the required data. The inpatient mortality was 20% (43/215), 15 of them in the first two weeks of treatment. In the final model (157 cases), adjusted for age, previous episode of CM, ART use, type of antifungal treatment, raised intracranial pressure, frequency of therapeutic lumbar punctures, baseline fungal burden and treatment period, the factors associated with early mycological clearance were: Amphotericin B deoxycholate plus fluconazole as combination therapy (RR, 1.56; 95% CI, 1.14-2.14); severe baseline intracranial pressure (≥35 cm H2O) (RR, 0.57; 95% CI, 0.33-0.99); and baseline fungal burden over 4.5 log10 CFU/mL (RR, 0.61 95% CI: 0.39-0.95). CONCLUSIONS: In a setting without access to first-line therapy for CM, the combination therapy with amphotericin B deoxycholate plus fluconazole was positively associated with early mycological clearance, while high fungal burden and severe baseline intracranial pressure were negatively associated, and thus related to failure.
Subject(s)
AIDS-Related Opportunistic Infections/microbiology , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Deoxycholic Acid/therapeutic use , Fluconazole/therapeutic use , HIV Infections/microbiology , Meningitis, Cryptococcal/microbiology , AIDS-Related Opportunistic Infections/drug therapy , AIDS-Related Opportunistic Infections/immunology , Adult , Colony Count, Microbial , Drug Combinations , Drug Therapy, Combination , Female , HIV Infections/drug therapy , HIV Infections/immunology , Humans , Immunocompromised Host , Male , Meningitis, Cryptococcal/drug therapy , Meningitis, Cryptococcal/immunology , Retrospective Studies , Risk Factors , Treatment OutcomeABSTRACT
BACKGROUND: Diagnosis of pulmonary tuberculosis (TB) among human immunodeficiency virus (HIV) patients remains complex and demands easy to perform and accurate tests. Xpert®MTB/RIF (MTB/RIF) is a molecular TB diagnostic test which is rapid and convenient; the test requires minimal human resources and reports results within two hours. The majority of performance studies of MTB/RIF have been performed in high HIV burden settings, thus TB diagnostic studies among HIV patients in low HIV prevalence settings such as Peru are still needed. METHODOLOGY/PRINCIPAL FINDINGS: From April 2010 to May 2011, HIV-positive patients with high clinical suspicion of TB were enrolled from two tertiary hospitals in Lima, Peru. Detection of TB by MTB/RIF was compared to a composite reference standard Löwenstein-Jensen (LJ) and liquid culture. Detection of rifampicin resistance was compared to the LJ proportion method. We included 131 patients, the median CD4 cell count was 154.5 cells/mm(3) and 45 (34.4%) had TB. For TB detection among HIV patients, sensitivity of MTB/RIF was 97.8% (95% CI 88.4-99.6) (44/45); specificity was 97.7% (95% CI 91.9-99.4) (84/86); the positive predictive value was 95.7% (95% CI 85.5-98.8) (44/46); and the negative predictive value, 98.8% (95% CI 93.6-99.8) (84/85). MTB/RIF detected 13/14 smear-negative TB cases, outperforming smear microscopy [97.8% (44/45) vs. 68.9% (31/45); p = 0.0002]. For rifampicin resistance detection, sensitivity of MTB/RIF was 100% (95% CI 61.0-100.0) (6/6); specificity was 91.0% (95% CI 76.4-96.9) (30/33); the positive predictive value was 66.7% (95% CI 35.4-87.9) (6/9); and the negative predictive value was 100% (95% CI 88.7 -100.0) (30/30). CONCLUSIONS/SIGNIFICANCE: In HIV patients in our population with a high clinical suspicion of TB, MTB/RIF performed well for TB diagnosis and outperformed smear microscopy.
Subject(s)
HIV Infections/complications , Tuberculosis, Pulmonary/diagnosis , Antitubercular Agents/therapeutic use , Humans , Peru/epidemiology , Rifampin/therapeutic use , Sensitivity and Specificity , Sputum/microbiology , Tuberculosis, Pulmonary/complications , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/epidemiologyABSTRACT
El virus linfotrópico humano tipo 1 (HTLV-1 [human T-lymphotropic virus]) es un retrovirus con amplia distribución mundial. Pertenece a la familia Retroviridae y a la subfamilia Oncovirinae. Es un virus linfotrópico que compromete principalmente linfocitos CD4. El HTLV-1 está relacionada como agente etiológico de la leucemia/linfoma de células T del adulto (LLTA) y de la mielopatía/paraparesia espástica tropical (M/PPET).
The human T-lymphotropic virus type 1 (HTLV-1 [human T-lymphotropic virus]) is a retrovirus with worldwide distribution. Belongs to the Retroviridae family and subfamily Oncovirinae. It is a lymphotropic virus that mainly involves CD4 lymphocytes. The HTLV-1 is related as the etiologic agent of leukemia / lymphoma, adult T-cell (ATLL) and myelopathy / tropical spastic paraparesis (M / PPET).
Subject(s)
Humans , Diagnosis , Sexually Transmitted Diseases , Breast Feeding , T-Lymphocytes , Human T-lymphotropic virus 1 , PeruABSTRACT
Objetivos: Determinar los factores asociados a la forma víscero hemolítica de loxoscelismo en pacientes admitidos al Hospital Nacional Cayetano Heredia y describir las características clínico epidemiológicas de esta enfermedad. Material y método: Estudio de casos y controles que incluyó a los pacientes hospitalizados en la institución indicada entre el 2000 y 2008 por loxoscelismo víscero-hemolítico (casos) y loxoscelismo cutáneo (controles), de acuerdo a definiciones operativas. Las variables fueron analizadas en un modelo de regresión logística ajustado por potenciales factores de confusión. Resultados: Se incluyeron 48 casos y 89 controles; no se encontraron diferencias en la media de las edades (33 años +/- 18 vs. 31 años +/- 20, p=0,27). En el análisis multivariado, la presentación víscero-hemolítica se asoció con la presencia de mordedura en el tórax (ORa 6,6; IC95% 1,5 a 28,7) y de manifestaciones sistémicas en las primeras 24 horas de la admisión, incluyendo fiebre (ORa 3,2; IC95% 1,3 a 8,1) y mal estado general (ORa 3,3; IC95% 1,3 a 8,1). La mortalidad fue de 18% en los casos y 0% en los controles. Conclusiones: La mordedura en tórax y la presencia de fiebre y malestado general durante las primeras 24 horas están asociadas al desarrollo de la forma víscero-hemolítica de loxoscelismo en este escenario.
Objectives: To determine clinical factors associated with the occurrence of visceral-hemolytic loxoscelism in patients admitted to Hospital Nacional Cayetano Heredia, and to describe both clinical and epidemiological features of this condition. Material and method: We conducted a case-control study including patients admitted to Hospital Nacional Cayetano Heredia in Lima, Peru, with a diagnosis of visceral-hemolytic loxoscelism (cases) and cutaneous loxoscelism (controls), between years 2000 and 2008. Variable were analyzed using a logistic regression model adjusting for potential confounding factors. Results: Forty-nine cases and 89 controls were included. Age of patients was similar in both groups (33 +/- 18 years vs. 31 +/- 20 years, p= 0,27). Visceral-hemolytic loxoscelism was associated with spider bites located in the thorax (OR: 7.3; 95% CI: 1.3-41.0) and with systemic manifestations, including fever (OR: 3.2, 95% CI: 1.3-8,1) and a poor general condition (OR: 3.3; 95% CI: 1.3-8.1). Mortality rates were 18% in cases and 0% in controls. Conclusions: Spider bites located in the thoracic area and the presence of fever and a poor general condition during the first 24 hours of hospitalization are associated with the occurrence of visceral-hemolyticloxoscelism.
Subject(s)
Humans , Male , Female , Spider Bites , Spider Venoms , Case-Control StudiesABSTRACT
Introducción: En mayo del 2004, el Ministerio de Salud (MINSA) en colaboración con el Fondo Global de lucha contra el SIDA, la tuberculosis y la malaria implementó el programa nacional (PN) para brindar terapia antiretroviral en forma gratuita a todos los pacientes infectados con el VIH con indicación de tratamiento de acuerdo a la guía del PN. Objetivos: Describir las características pre-tratamiento antiretroviral, respuesta a la terapia antiretroviral de gran actividad (TARGA), toxicidad y tasa de mortalidad de la población de pacientes que iniciaron TARGA a través del PN en un hospital general. Material y Métodos: Revisamos las historias clínicas, fichas médicas, resultados de laboratorio y tarjetas de TARGA de todos los pacientes enrolados en el PN en el Hospital Nacional Cayetano Heredia (HNCH) y describimos las características pre-tratamiento antiretroviral, respuesta a la TARGA, toxicidad y tasa de mortalidad. Los pacientes seleccionados para este estudio fueron sujetos infectados con el VIH que: (i) tenían 18 años o más; (ii) iniciaron TARGA en el PN entre mayo 2004 y abril 2006; y (iii) no habían recibido terapia antiretroviral anteriormente (naïve). Se consideró como éxito virológico a la presencia de por lo menos un valor de carga viral indetectable (VIH-1 ARN < 400 copias/mL) entre los 3-6 meses posteriores al inicio de la TARGA...
Subject(s)
Humans , Male , Female , Anti-Retroviral Agents/therapeutic use , Patients , Treatment Outcome , Antiretroviral Therapy, Highly Active , PeruABSTRACT
El artículo tiene como objetivo presentar una revisión de aspectos clínicos de la infección por el virus linfotrópico humano de células T tipo 1 (HTLV-1), poniendo énfasis en información relevante para los médicos en el Perú. Luego de presentar algunos aspectos virológicos y epidemiológicos, tratamos los temas de la transmisión y de las enfermedades asociadas con el virus. Se discute específicamente las siguientes enfermedades asociadas: leucemia linfoma de células T del adulto, paraparesia espástica tropical, estrongiloidiasis, sarna, tuberculosis, dermatitis infectiva y coinfección con VIH. En conclusión, HTLV-1 es una infección endémica en el Perú. El espectro de enfermedades asociadas comprende síndromes inflamatorios, enfermedades linfoproliferativas e infecciones oportunistas.
This article is a review of clinical aspects of human type 1 T-cell lymphotropic virus (HTLV-1), with emphasis in relevant information for Peruvian physicians. After showing some virological and epidemiological data, transmission is reviewed, as well as diseases associated with this infection. The following associated conditions are specifically discussed: adult T-cell leukemia/lymphoma, tropical spastic paraparesis, strongyloidiasis, scabies, tuberculosis, infective dermatitis, and human immunodeficiency virus (HIV) coinfection. This review allows us to conclude that HTLV-1 is an endemic infection in Peru and that it is related to diseases with different patho-physiological mechanisms, including inflamatory syndromes, lymphoproliferative diseases and opportunistic infections.
Subject(s)
Humans , HIV , Human T-lymphotropic virus 1ABSTRACT
Objetivos: Describir las características clínico-epidemiológicas y la mortalidad de pacientes hospitalizados con tuberculosis (TBC) en el Departamento de Enfermedades Infecciosas, Tropicales y Dermatológicas del Hospital Nacional Cayetano Heredia (DEITD-HNCH) de Lima, Perú. Material y Métodos: Estudio retrospectivo y observacional que incluyó a pacientes hospitalizados desde enero de 1990 hasta diciembre de 2000 con diagnóstico de TBC definitiva o probable. Resultados: Se registraron 1340 altas con diagnóstico de TBC (18.7 por ciento). La edad promedio de los pacientes hospitalizados con TBC fue 33.5 más menos 15.1 años, 69.2 por ciento fueron varones y 28.1 por ciento infección por el Virus de Inmunodeficiencia Humana(VIH). La mortalidad por TBC fue 17.2 por ciento y permaneció constante durante el período. El número de muertes por TBC (230 pacientes) representó el 37.5 por ciento de las muertes por todas las causas (613 pacientes). De los fallecidos por TBC, 151 (65.6 por ciento) tuvieron TBC multisistémica, 60 (26.1 por ciento) TBC pulmonar y 19 (8.3 por ciento) TBC extrapulmonar exclusiva. Hubo sospecha clínica de TBC multidrogorresistente (TBC-MDR) en 51 (22.2 por ciento) pacientes fallecidos. Edad mayor de 30 años (OR = 1.6, 1.2 menor que OR menor 2.1) y tener infección por el VIH (OR = 5.4, 4.0 menor que OR menor que 7.3), constituyeron factores asociados a mortalidad en el análisis multivariado de los pacientes con TBC. Conclusiones: Tuberculosis representó el 18.7 por ciento del total de diagnósticos y el 37.5 por ciento de las muertes por todas las causas. La mortalidad relacionada con TBC en la unidad de enfermedades infecciosas de un hospital público referencial no ha disminuido en los últimos 11 años. Infección por VIH y ser mayor de 30 años están asociados a mortalidad.
